Rolf Wahlqvist
Papers
1
Total Citations
19
H-Index
1
About
Rolf Wahlqvist is a leading urologic oncologist whose research centers on testicular cancer, with a particular focus on refining treatment strategies to minimize long-term toxicity. His major contribution lies in pioneering the use of primary retroperitoneal lymph node dissection (RPLND) as an alternative to standard cytotoxic therapy for low-volume metastatic seminoma. In his landmark 2024 study, conducted through the Swedish Norwegian Testicular Cancer Group, Wahlqvist demonstrated that RPLND can achieve excellent oncological outcomes while sparing patients the lifelong morbidity associated with chemotherapy and radiation. This population-based cohort study, already garnering 19 citations, represents a paradigm shift in clinical practice, offering a surgical path to cure without systemic toxicity. Wahlqvist’s work directly addresses the critical unmet need for de-escalation of treatment in young men with testicular cancer, positioning him as a key figure in the movement toward personalized, morbidity-sparing cancer care. His research continues to shape international guidelines and inspire further investigation into surgical management of germ cell tumors.
Research Focus
Key Achievements
Top Papers
- 1